Showing 8571-8580 of 21414 results for "".
Concentrating on the MOMPOD Trial for Metformin Plus Insulin
https://reachmd.com/programs/diabetes-discourse/concentrating-on-the-mompod-trial-for-metformin-plus-insulin/17887/Tune in to find out about how metformin plus insulin can help patients with preexisting diabetes or gestational diabetes.Getting to Know GRADE: A Comparative Study of T2D Treatment
https://reachmd.com/programs/diabetes-discourse/getting-to-know-grade-a-comparative-study-of-t2d-treatment/14216/An ancillary study from the landmark GRADE study explores the efficacy of different treatments for type 2 diabetes. What do we need to know about them?Special Report: What Went Wrong With ACCORD?
https://reachmd.com/programs/clinicians-roundtable/special-report-what-went-wrong-with-accord/3205/What went wrong with the glucose-lowering arm of the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Trials? Intensive therapy was expected to reduce cardiovascular events in Type 2 diabetics at high risk of cardiovascular disease. Instead, it appears to have led to an increase in moToward Precision Medicine for Genetic Epilepsies: Glucose Transporter Type 1 Deficiency Syndrome
https://reachmd.com/diseases-diagnoses/epilepsy-seizures/toward-precision-medicine-for-genetic-epilepsies-glucose-transporter-type-1-deficiency-syndrome/32055/As we begin to understand the mechanisms of specific genetic epilepsies, tailored treatments have the potential to be transformative, as in GLUT1-DS.What is the Safety of Statins in Patients with Diabetes?
https://reachmd.com/programs/lipid-luminations/what-is-the-safety-of-statins-in-patients-with-diabetes/6967/At the most recent National Lipid Association (NLA) meeting, host Dr. Alan Brown welcomes Kevin Maki, PhD, FNLA, CLS, Chief Science Officer for Midwest Center for Metabolic and Cardiovascular Research and Adjunct Faculty position in Biostatistics and Applied Epidemiology at DePaul University, ChicagAIP Emerges as a Potential Marker for Diabetic Kidney Risk
https://reachmd.com/programs/clinicians-roundtable/aip-emerges-as-a-potential-marker-for-diabetic-kidney-risk/37220/Update on Diabetic Gastroparesis
https://reachmd.com/programs/clinicians-roundtable/update-on-diabetic-gastroparesis/1870/Dr. William Chey reviews newer thinking on the pathophysiology and treatment of this difficult disorder.Exploring IGF1R as a New Therapeutic Target in Myasthenia Gravis
https://reachmd.com/programs/neurofrontiers/exploring-igf1r-as-a-new-therapeutic-target-in-myasthenia-gravis/35491/A recent study explored the potential roles of uric acid and the type 1 insulin-like growth factor receptor in the development and progression of myasthenia gravis (MG). Read about the findings and their implications for MG care.Updated AACE Guidance on Managing Dyslipidemia in T2D
https://reachmd.com/programs/heart-matters/aace-guideline-updates-dyslipidemia-t2d/54149/Dyslipidemia is a major driver of cardiovascular risk in patients with type 2 diabetes (T2D), and lipid management is a key component of the 2026 AACE diabetes algorithm. Join Dr. Scott Isaacs as he reviews new recommendations on LDL-C goals and individualized care in this population. Dr. Isaacs isSports related brain injuries
https://reachmd.com/programs/clinicians-roundtable/sports-related-brain-injuries/7/Pulmonologist, Dr. Ankin, discusses the types and prevalence of sports related brain injuries and sleep disorder breathing.